` ZLDPF (Zealand Pharma A/S) vs S&P 500 Comparison - Alpha Spread

ZLDPF
vs
S&P 500

Over the past 12 months, ZLDPF has underperformed S&P 500, delivering a return of -25% compared to the S&P 500's +17% growth.

Stocks Performance
ZLDPF vs S&P 500

Loading
ZLDPF
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ZLDPF vs S&P 500

Performance Gap Between ZLDPF and GSPC
HIDDEN
Show

Performance By Year
ZLDPF vs S&P 500

Loading
ZLDPF
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Zealand Pharma A/S vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Zealand Pharma A/S
Glance View

Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.

ZLDPF Intrinsic Value
HIDDEN
Show
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett